Brain malformation-congenital heart disease-postaxial polydactyly syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for Brain malformation-congenital heart disease-postaxial polydactyly syndrome.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Brain malformation-congenital heart disease-postaxial polydactyly syndrome.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

XARELTO

(RIVAROXABAN)standard

Janssen Pharmaceuticals, Inc.

Factor Xa Inhibitor [EPC]

12.1 Mechanism of Action XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Brain malformation-congenital heart disease-postaxial polydactyly syndrome.
Search all trials →
Search clinical trials for Brain malformation-congenital heart disease-postaxial polydactyly syndrome

Recent News & Research

No recent news articles indexed yet for Brain malformation-congenital heart disease-postaxial polydactyly syndrome.
Search PubMed for Brain malformation-congenital heart disease-postaxial polydactyly syndrome

Browse all Brain malformation-congenital heart disease-postaxial polydactyly syndrome news →

Specialist Network

No specialists currently listed for Brain malformation-congenital heart disease-postaxial polydactyly syndrome.

View all Brain malformation-congenital heart disease-postaxial polydactyly syndrome specialists →

Quick Actions